KU-55933 Chemical Properties

Boiling point:

628.0±55.0 °C(Predicted)

Density 

1.419±0.06 g/cm3(Predicted)

storage temp. 

-20°C

solubility 

Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 20 mg/ml)

form 

powder

pka

0.33±0.20(Predicted)

color 

white to beige

Stability:

Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 1 month.

Safety Information

WGK Germany 

3

KU-55933 Usage And Synthesis

Description

Potent and selective ATM kinase inhibitor IC50s= 13, 2500, 9300, 16600, >100000 and >100000 nM for ATM, DNA-PK, mTOR, PI 3-kinase, PI 4-K and ATR respectively.1Decreases viability of MCF-7, A549 and HCT116 cells and decreases p21CIP1?levels?in vitro.2?Disruption of ATM signaling in primary A-T fibroblasts leads to dysregulation of ribonucleotide reductase and increase resistance to inhibitors of mitochondrial respiration and translation.3?Sensitizes radio-resistant cancer cells.4Provides neuroprotection against H2O2-induced cell damage.5

Uses

A potent and specific ATM kinase inhibitor with an IC50 and a Ki of 13 nM and 2.2 nM, respectively.

Uses

KU-55933 has been used as an ataxia-telangiectasia mutated (Atm) inhibitor.

Definition

ChEBI: 2-(4-morpholinyl)-6-(1-thianthrenyl)-4-pyranone is a thianthrene.

Biological Activity

Potent, selective and competitive ATM kinase inhibitor (K i = 2.2 nM, IC 50 values are 13, 2500, 9300, 16600, > 100000 and > 100000 nM at ATM, DNA-PK, mTOR, PI 3-kinase, PI 4-K and ATR respectively). Decreases viability of MCF-7, A549 and HCT116 cells and decreases p21 CIP1 levels in vitro . Acts as a radio- and chemosensitizer for the treatment of cancer.

Biochem/physiol Actions

KU-55933 is a very potent, specific inhibitor of Ataxia telangiectasia (A-T) mutated (ATM) kinase (IC50 = 13 nM). KU-22933 treatment sensitizes cancer cells to ionizing radiation and cytotoxic drugs. The compound KU-22933 blocks ATM-mediated phosphorylyation of p53, gH2AX, NBS1, and SMC1.

storage

Desiccate at -20°C

References

1) Hickson?et al.?(2004),?Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; Cancer Res.,?64?9152 2) Crescenzi?et al.?(2008),?Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy; Clin. Cancer Res.?14?1877 3) Eaton?et al.?(2007),?Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis; J. Clin. Invest.,?117?2723 4) Zhang?et al.?(2015)?The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect; Int. J. Radiat. Biol.,?91?368 5) Chwastek?et al.?(2017)?The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a yH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D; Int. J. Biochem. Cell Biol.?87?38

KU-55933(587871-26-9)Related Product Information

• D-ERYTHRO-SPHINGOSINE
• NU7441 (KU-57788)
• Bortezomib
• Y27632 (hydrochloride)
• VE-821
• KU-60019
• Olaparib
• PLX-4720
• CX-4945
• Fluoxetine hydrochloride
• Alpelisib (BYL719)
• Tubastatin A hydrochloride
• N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide hydrochloride
• BI 2536
• Neratinib
• Glucagon Receptor Antagonist I
• KU-55933 (ATM Kinase Inhibitor)
• Thianthrene